CYPHERPUNK TECHNOLOGIES INC. Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CYPHERPUNK TECHNOLOGIES INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2021-12-31 was $939.00K.
- CYPHERPUNK TECHNOLOGIES INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2021-09-30 was $40.00K.
- CYPHERPUNK TECHNOLOGIES INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2021-03-31 was $14.00K, a 89.06% decline year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. stock issued during period, value, conversion of convertible securities for fiscal 2021 was $993.00K, a 185.34% increase from fiscal 2020.
- CYPHERPUNK TECHNOLOGIES INC. stock issued during period, value, conversion of convertible securities for fiscal 2020 was $348.00K.
- CYPHERPUNK TECHNOLOGIES INC. stock issued during period, value, conversion of convertible securities for fiscal 2018 was $2.35M, a 96.68% decline from fiscal 2017.
- CYPHERPUNK TECHNOLOGIES INC. stock issued during period, value, conversion of convertible securities for fiscal 2017 was $70.78M.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2021-12-31 | $939.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $993.00K 10-K · filed 2023-03-24 |
| 2021-09-30 | $40.00K 10-Q · filed 2022-11-14 | $54.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $14.00K derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $14.00K 10-Q · filed 2022-05-13 | $234.00K derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $348.00K 10-K · filed 2022-03-11 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | |
| 2020-06-30 | $220.00K 10-Q · filed 2021-08-13 | |
| 2020-03-31 | $128.00K 10-Q · filed 2021-05-14 | |
| 2018-12-31 | $2.35M 10-K · filed 2020-03-16 | |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $70.78M 10-K · filed 2019-04-01 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | |
| 2017-03-31 | $70.78M 10-Q · filed 2017-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |